Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
11.216 CHF
−486.43 M CHF
9.98 B CHF
255.62 M
About Vertex Pharmaceuticals Incorporated
Sector
Industry
CEO
Reshma Kewalramani
Website
Headquarters
Boston
Founded
1989
ISIN
US92532F1003
FIGI
BBG006TLX2W2
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 306.263 CHF — it has decreased by −5.10% in the past 24 hours. Watch Vertex Pharmaceuticals Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Vertex Pharmaceuticals Incorporated stocks are traded under the ticker VX1.
VX1 stock has fallen by −5.10% compared to the previous week, the month change is a −5.10% fall, over the last year Vertex Pharmaceuticals Incorporated has showed a −24.36% decrease.
We've gathered analysts' opinions on Vertex Pharmaceuticals Incorporated future price: according to them, VX1 price has a max estimate of 496.22 CHF and a min estimate of 262.43 CHF. Watch VX1 chart and read a more detailed Vertex Pharmaceuticals Incorporated stock forecast: see what analysts think of Vertex Pharmaceuticals Incorporated and suggest that you do with its stocks.
VX1 stock is 5.37% volatile and has beta coefficient of 0.48. Track Vertex Pharmaceuticals Incorporated stock price on the chart and check out the list of the most volatile stocks — is Vertex Pharmaceuticals Incorporated there?
Today Vertex Pharmaceuticals Incorporated has the market capitalization of 78.96 B, it has decreased by −3.46% over the last week.
Yes, you can track Vertex Pharmaceuticals Incorporated financials in yearly and quarterly reports right on TradingView.
Vertex Pharmaceuticals Incorporated is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
VX1 earnings for the last quarter are 3.59 CHF per share, whereas the estimation was 3.39 CHF resulting in a 5.80% surprise. The estimated earnings for the next quarter are 3.67 CHF per share. See more details about Vertex Pharmaceuticals Incorporated earnings.
Vertex Pharmaceuticals Incorporated revenue for the last quarter amounts to 2.34 B CHF, despite the estimated figure of 2.31 B CHF. In the next quarter, revenue is expected to reach 2.44 B CHF.
VX1 net income for the last quarter is 819.50 M CHF, while the quarter before that showed 572.13 M CHF of net income which accounts for 43.24% change. Track more Vertex Pharmaceuticals Incorporated financial stats to get the full picture.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 30, 2025, the company has 6.1 K employees. See our rating of the largest employees — is Vertex Pharmaceuticals Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vertex Pharmaceuticals Incorporated EBITDA is 3.65 B CHF, and current EBITDA margin is 41.56%. See more stats in Vertex Pharmaceuticals Incorporated financial statements.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vertex Pharmaceuticals Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vertex Pharmaceuticals Incorporated technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vertex Pharmaceuticals Incorporated stock shows the strong sell signal. See more of Vertex Pharmaceuticals Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.